NDATOPICALAEROSOL, FOAM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
AMZEEQ (minocycline) by Journey Medical is 12. First approved in 2019.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMZEEQ is a topical aerosol foam formulation of minocycline approved for acne vulgaris in patients 10 years and older. The mechanism of action is unknown, though minocycline is active in vitro against Propionibacterium acnes with low propensity for resistance development. It is applied topically to the face, neck, upper chest, upper back, shoulders, and upper arms once daily.
$0.025BPart D
Peak10.8 years to LOEProduct is at peak lifecycle with minimal market penetration ($25K Part D spending, 50 claims in 2023), suggesting a mature but niche commercial operation with limited team expansion.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of AMZEEQ for the treatment of acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of AMZEEQ for the treatment of acne are unknown. 12.3 Pharmacokinetics In a pharmacokinetic study, male and female subjects 18 years of age or older with acne…
Indications
Worked on AMZEEQ at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.